| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $692,777 | 3 | 100 |
Sells | $0 | 0 | 0 |
| RECANATI LEON | director | 2 | $692,100 | 0 | $0 | $692,100 |
| Tarcic Gabi | Chief Development Officer | 1 | $677 | 0 | $0 | $677 |
Evogene Ltd., along with its subsidiaries, operates as a computational biology firm. Its core activity involves the discovery and advancement of products across diverse life-science sectors, such as human health and agriculture, primarily leveraging its proprietary Computational Predictive Biology (CPB) platform. This platform, built on deep biological insights, big data analytics, and artificial intelligence, is engineered to digitally identify and strategically guide the creation of life-science solutions derived from microbes, small …
Over the last 12 months, insiders at Evogene Ltd. have bought $692,777 and sold $0 worth of Evogene Ltd. stock.
On average, over the past 5 years, insiders at Evogene Ltd. have bought $692,777 and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: RECANATI LEON (director) — $692,100. Tarcic Gabi (Chief Development Officer) — $677.
The last purchase of 460,000 shares for transaction amount of $292,100 was made by RECANATI LEON (director) on 2026‑08‑11.
| 2026-08-11 | RECANATI LEON | director | 460,000 4.8392% | $0.64 | $292,100 | -35.43% | ||
| 2026-08-04 | RECANATI LEON | director | 800,000 7.1417% | $0.50 | $400,000 | -26.10% | ||
| 2026-06-04 | Tarcic Gabi | Chief Development Officer | 1,129 0.0129% | $0.60 | $677 | -18.68% |
| Increased Positions | 6 | +28.57% | 63,526 | +41.17% |
| Decreased Positions | 8 | -38.1% | 36,096 | -23.39% |
| New Positions | 5 | New | 32,337 | New |
| Sold Out Positions | <1 | Sold Out | 11,406 | Sold Out |
| Total Postitions | 19 | -9.52% | 181,724 | +17.78% |